 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H13NO2 |
| Molar mass | 191.230 g·mol−1 |
| 3D model (JSmol) | |
| |
6,7-Methylenedioxy-2-aminotetralin (MDAT) is adrug developed in the 1990s by a team atPurdue University led byDavid E. Nichols.[1] It appears to act as aserotonin releasing agent based on rodent drug discrimination assays comparing it toMDMA, in which it fully substitutes for, and additionally lacks any kind ofserotonergicneurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putativeentactogen in humans.
